Longeveron Inc. (NASDAQ: LGVN) stock gained by 135.27% at last close however its hiked by 50.95% in the after-hours trading session, as well. Longeveron is a clinical-stage biotechnology business focused on creating cellular therapeutics for age-related and life-threatening diseases.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Sponsored
LGVN stock’ Significant Update
The FDA has given Lomecel-B RPD designation for the cure of Hypoplastic Left Heart Syndrome (HLHS), a severe and life-threatening congenital heart condition in neonates, according to Longeveron. In a Phase 2 trial, Lomecel-B, an experimental allogeneic bone marrow-derived medical signalling cell (MSC) product, is being examined.
A Backdoor Way To Profit From Today’s Crypto Bull Market
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Sponsored
Every year, about 1,000 babies in the United States are delivered with HLHS. The left ventricle of HLHS new-borns is underdeveloped, impairing the heart’s ability to pump blood to the whole body. Without surgical treatment, HLHS is frequently fatal. Three surgical procedures are conducted over a 5-year period to enable the right ventricle to be designed to pump blood to the body. Longeveron is testing the safety of injecting Lomecel-B into the right ventricle during the second operation (4–6 months of age), as well as the influence on heart function and other health outcomes.
Also,
Longeveron recently released the findings of their Lomecel-B safety-focused Phase I clinical research in HLHS participants. The cells were well accepted when cardiologists administered Lomecel-B directly into the newborns’ hearts during surgery, with no severe negative cardiac events or infections linked to the exploratory treatment.
Between 2 and 3.5 years after surgery, 100% of the infants who participated in the Phase 1 trial (n=10) were living and had not needed a transplant. Other health indicators, such as weight gain and growth patterns, were comparable to that of healthy babies.
Moreover,
The FDA may give RPD status to disorders that mainly affect children aged 18 and under and impact fewer than 200,000 people in the United States. If the FDA approves Lomecel-B for the cure of HLHS, Longeveron may also be qualified for a priority review voucher (PRV). It can happen if the application for the medicine meets specific criteria and is approved by September 30, 2026, as required by existing law.
